NYSEAMERICAN:NSRX Nasus Pharma (NSRX) Stock Price, News & Analysis $3.48 0.00 (0.00%) Closing price 09/25/2026 04:10 PM EasternExtended Trading$3.44 -0.04 (-1.18%) As of 09/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsSEC Filings About Nasus Pharma Stock (NYSEAMERICAN:NSRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nasus Pharma alerts:Sign Up Key Stats Today's Range$3.43▼$3.6050-Day Range$2.91▼$4.1052-Week Range$1.98▼$9.50Volume20,956 shsAverage Volume9,437 shsMarket Capitalization$40.75 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview Nasus Pharma Ltd. is an Israel-based specialty pharmaceutical company focused on developing intranasal treatments for acute medical conditions. The company’s platform is designed to deliver drug powders through the nose, with the goal of offering convenient, needle-free alternatives to certain injectable therapies. Nasus Pharma’s development activities center on intranasal pharmaceutical products intended for rapid administration in emergency and urgent-care settings. Its pipeline has included candidates targeting conditions in which fast drug delivery may be important, although the availability and development status of individual products may change as clinical and regulatory work progresses. The company conducts its research and development activities in Israel and is seeking to advance its intranasal drug-delivery technology for potential use in international markets. Nasus Pharma’s shares trade on the NYSE American under the symbol NSRX.AI Generated. May Contain Errors. Read More Nasus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreNSRX MarketRank™: Nasus Pharma scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNasus Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialNasus Pharma has a consensus price target of $18.00, representing about 417.2% upside from its current price of $3.48.Amount of Analyst CoverageNasus Pharma has received no research coverage in the past 90 days.Read more about Nasus Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nasus Pharma are expected to grow in the coming year, from ($0.93) to ($0.85) per share.Price to Book Value per Share RatioNasus Pharma has a P/B Ratio of 11.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.69% of the float of Nasus Pharma has been sold short.Short Interest Ratio / Days to CoverNasus Pharma has a short interest ratio ("days to cover") of 7.96.Change versus previous monthShort interest in Nasus Pharma has recently decreased by 7.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNasus Pharma does not currently pay a dividend.Dividend GrowthNasus Pharma does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows4 people have added Nasus Pharma to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nasus Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsNasus Pharma has minimal institutional ownership at this time.Read more about Nasus Pharma's insider trading history. Receive NSRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nasus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NSRX Stock News HeadlinesNasus Pharma Sets Up $8.5 Million At-the-Market Equity Program to Fund Clinical PipelineSeptember 18, 2026 | tipranks.comNasus Pharma's IND Application For NS002 Gets FDA ClearanceSeptember 14, 2026 | rttnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 27 at 1:00 AM | Weiss Ratings (Ad)Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis TrialSeptember 14, 2026 | tipranks.comNasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of AnaphylaxisSeptember 14, 2026 | globenewswire.comNasus Pharma to Present at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | quiverquant.comQNasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | globenewswire.comNasus Pharma Boosts Cash and Equity in First-Half 2026 FilingAugust 20, 2026 | theglobeandmail.comSee More Headlines NSRX Stock Analysis - Frequently Asked Questions How have NSRX shares performed this year? Nasus Pharma's stock was trading at $7.10 at the beginning of 2026. Since then, NSRX shares have decreased by 51.0% and is now trading at $3.48. How were Nasus Pharma's earnings last quarter? Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) posted its quarterly earnings data on Monday, August, 17th. The company reported ($0.27) earnings per share for the quarter. How do I buy shares of Nasus Pharma? Shares of NSRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/17/2026Today9/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NSRX's financial health is in the Green zone, according to TradeSmith. NSRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:NSRX CIK2029039 Webwww.nasuspharma.com Phone972-3573-6632FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Nasus Pharma$18.00 High Price Target$18.00 Low Price Target$18.00 Potential Upside/Downside+417.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.77 Quick Ratio2.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book11.23Miscellaneous Outstanding Shares11,710,000Free FloatN/AMarket Cap$40.75 million OptionableN/A BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSEAMERICAN:NSRX) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nasus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nasus Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
